Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 289

1.

Cost-effectiveness of integrating postpartum antiretroviral therapy and infant care into maternal & child health services in South Africa.

Dugdale CM, Phillips TK, Myer L, Hyle EP, Brittain K, Freedberg KA, Cunnama L, Walensky RP, Zerbe A, Weinstein MC, Abrams EJ, Ciaranello AL; MCH-ART Trial Team.

PLoS One. 2019 Nov 15;14(11):e0225104. doi: 10.1371/journal.pone.0225104. eCollection 2019.

2.

Shortened Tuberculosis Treatment for People with HIV in South Africa: A Model-based Evaluation and Cost-effectiveness Analysis.

Reddy KP, Horsburgh CR, Wood R, Fields NF, Girouard MP, Costantini S, Hou T, Freedberg KA, Walensky RP.

Ann Am Thorac Soc. 2019 Nov 5. doi: 10.1513/AnnalsATS.201905-418OC. [Epub ahead of print]

PMID:
31689133
3.

Effect of PEPFAR funding policy change on HIV service delivery in a large HIV care and treatment network in Nigeria.

Banigbe B, Audet CM, Okonkwo P, Arije OO, Bassi E, Clouse K, Simmons M, Aliyu MH, Freedberg KA, Ahonkhai AA.

PLoS One. 2019 Sep 25;14(9):e0221809. doi: 10.1371/journal.pone.0221809. eCollection 2019.

4.

Cost-Effectiveness of Preemptive Switching to Efavirenz-Based Antiretroviral Therapy for Children With Human Immunodeficiency Virus.

Desmonde S, Frank SC, Coovadia A, Dahourou DL, Hou T, Abrams EJ, Amorissani-Folquet M, Walensky RP, Strehlau R, Penazzato M, Freedberg KA, Kuhn L, Leroy V, Ciaranello AL.

Open Forum Infect Dis. 2019 Jun 11;6(7):ofz276. doi: 10.1093/ofid/ofz276. eCollection 2019 Jul.

5.

Rapid, point-of-care diagnosis of tuberculosis with novel Truenat assay: Cost-effectiveness analysis for India's public sector.

Lee DJ, Kumarasamy N, Resch SC, Sivaramakrishnan GN, Mayer KH, Tripathy S, Paltiel AD, Freedberg KA, Reddy KP.

PLoS One. 2019 Jul 2;14(7):e0218890. doi: 10.1371/journal.pone.0218890. eCollection 2019.

6.

Cost-effectiveness and budget impact of immediate antiretroviral therapy initiation for treatment of HIV infection in Côte d'Ivoire: A model-based analysis.

Ouattara EN, MacLean RL, Danel C, Borre ED, Gabillard D, Huang M, Moh R, Paltiel AD, Eholié SP, Walensky RP, Anglaret X, Freedberg KA.

PLoS One. 2019 Jun 27;14(6):e0219068. doi: 10.1371/journal.pone.0219068. eCollection 2019.

7.

Using national laboratory data to assess cumulative frequency of linkage after transfer to community-based HIV clinics in South Africa.

Bassett IV, Huang M, Cloete C, Candy S, Giddy J, Frank SC, Freedberg KA, Losina E, Walensky RP, Parker RA.

J Int AIDS Soc. 2019 Jun;22(6):e25326. doi: 10.1002/jia2.25326.

8.

What risk of death would people take to be cured of HIV and why? A survey of people living with HIV.

Murray BR, Kratka A, Scherr KA, Eyal N, Blumenthal-Barby J, Freedberg KA, Kuritzkes DR, Hammitt JK, Edifor R, Katz MN, Pollak KI, Zikmund-Fisher BJ, Halpern SD, Barks MC, Ubel PA.

J Virus Erad. 2019 Apr 1;5(2):109-115.

9.

HIV testing in a large community health center serving a multi-cultural patient population: A qualitative study of providers.

James AJ, Marable D, Cubbison CV, Tarbox AA, Mejia DL, Oo SA, Freedberg KA, Levison JH.

AIDS Care. 2019 Dec;31(12):1585-1592. doi: 10.1080/09540121.2019.1612016. Epub 2019 May 27.

PMID:
31131623
10.

Cost-effectiveness of integrating buprenorphine-naloxone treatment for opioid use disorder into clinical care for persons with HIV/hepatitis C co-infection who inject opioids.

Barocas JA, Morgan JR, Fiellin DA, Schackman BR, Eftekhari Yazdi G, Stein MD, Freedberg KA, Linas BP.

Int J Drug Policy. 2019 Oct;72:160-168. doi: 10.1016/j.drugpo.2019.05.010. Epub 2019 May 10.

PMID:
31085063
11.

Clinical impact and cost-effectiveness of genotype testing at HIV diagnosis in the United States.

Hyle EP, Scott JA, Sax PE, Millham LRI, Dugdale CM, Weinstein MC, Freedberg KA, Walensky RP.

Clin Infect Dis. 2019 May 4. pii: ciz372. doi: 10.1093/cid/ciz372. [Epub ahead of print]

PMID:
31055599
12.

Model-Based Methods to Translate Adolescent Medicine Trials Network for HIV/AIDS Interventions Findings Into Policy Recommendations: Rationale and Protocol for a Modeling Core (ATN 161).

Neilan AM, Patel K, Agwu AL, Bassett IV, Amico KR, Crespi CM, Gaur AH, Horvath KJ, Powers KA, Rendina HJ, Hightow-Weidman LB, Li X, Naar S, Nachman S, Parsons JT, Simpson KN, Stanton BF, Freedberg KA, Bangs AC, Hudgens MG, Ciaranello AL.

JMIR Res Protoc. 2019 Apr 16;8(4):e9898. doi: 10.2196/resprot.9898.

13.

Risks and Benefits of Dolutegravir- and Efavirenz-Based Strategies for South African Women With HIV of Child-Bearing Potential: A Modeling Study.

Dugdale CM, Ciaranello AL, Bekker LG, Stern ME, Myer L, Wood R, Sax PE, Abrams EJ, Freedberg KA, Walensky RP.

Ann Intern Med. 2019 May 7;170(9):614-625. doi: 10.7326/M18-3358. Epub 2019 Apr 2.

14.

The Cost-effectiveness of HIV Pre-exposure Prophylaxis and HIV Testing Strategies in High-risk Groups in India.

Kazemian P, Costantini S, Kumarasamy N, Paltiel AD, Mayer KH, Chandhiok N, Walensky RP, Freedberg KA.

Clin Infect Dis. 2019 Mar 28. pii: ciz249. doi: 10.1093/cid/ciz249. [Epub ahead of print]

PMID:
30921454
15.

Modelling the epidemiologic impact of achieving UNAIDS fast-track 90-90-90 and 95-95-95 targets in South Africa.

Abuelezam NN, McCormick AW, Surface ED, Fussell T, Freedberg KA, Lipsitch M, Seage GR.

Epidemiol Infect. 2019 Jan;147:e122. doi: 10.1017/S0950268818003497.

16.

Cost of an HIV Medical Care Coordination Program in Los Angeles County.

Schackman BR, Jeng PJ, Flash MJE, Mejia M, Oksuzyan S, Scott JA, Freedberg KA, Kulkarni SP, Garland WH.

J Acquir Immune Defic Syndr. 2019 May 1;81(1):e15-e17. doi: 10.1097/QAI.0000000000001994. No abstract available.

PMID:
30865169
17.

Clinical effect and cost-effectiveness of incorporation of point-of-care assays into early infant HIV diagnosis programmes in Zimbabwe: a modelling study.

Frank SC, Cohn J, Dunning L, Sacks E, Walensky RP, Mukherjee S, Dugdale CM, Turunga E, Freedberg KA, Ciaranello AL.

Lancet HIV. 2019 Mar;6(3):e182-e190. doi: 10.1016/S2352-3018(18)30328-X. Epub 2019 Feb 5.

PMID:
30737187
18.

Prevention of Prescription Opioid Misuse and Projected Overdose Deaths in the United States.

Chen Q, Larochelle MR, Weaver DT, Lietz AP, Mueller PP, Mercaldo S, Wakeman SE, Freedberg KA, Raphel TJ, Knudsen AB, Pandharipande PV, Chhatwal J.

JAMA Netw Open. 2019 Feb 1;2(2):e187621. doi: 10.1001/jamanetworkopen.2018.7621.

19.

Cost-effectiveness of urine-based tuberculosis screening in hospitalised patients with HIV in Africa: a microsimulation modelling study.

Reddy KP, Gupta-Wright A, Fielding KL, Costantini S, Zheng A, Corbett EL, Yu L, van Oosterhout JJ, Resch SC, Wilson DP, Horsburgh CR Jr, Wood R, Alufandika-Moyo M, Peters JA, Freedberg KA, Lawn SD, Walensky RP.

Lancet Glob Health. 2019 Feb;7(2):e200-e208. doi: 10.1016/S2214-109X(18)30436-4.

20.

Subclinical tuberculosis among adults with HIV: clinical features and outcomes in a South African cohort.

Bajema KL, Bassett IV, Coleman SM, Ross D, Freedberg KA, Wald A, Drain PK.

BMC Infect Dis. 2019 Jan 5;19(1):14. doi: 10.1186/s12879-018-3614-7.

21.

HIV Testing After a First Positive Rapid Diagnostic Test: A Role for Nucleic Acid Testing?

Neilan AM, Cohn JE, Lemaire JF, Sacks E, Alban R, Freedberg KA, Walensky RP, Ciaranello AL.

Open Forum Infect Dis. 2018 Aug 29;5(8):ofy170. doi: 10.1093/ofid/ofy170. eCollection 2018 Aug.

22.

Voluntary Community Human Immunodeficiency Virus Testing, Linkage, and Retention in Care Interventions in Kenya: Modeling the Clinical Impact and Cost-effectiveness.

Luong Nguyen LB, Yazdanpanah Y, Maman D, Wanjala S, Vandenbulcke A, Price J, Parker RA, Hennequin W, Mendiharat P, Freedberg KA.

Clin Infect Dis. 2018 Aug 16;67(5):719-726. doi: 10.1093/cid/ciy173.

23.

Optimal breastfeeding durations for HIV-exposed infants: the impact of maternal ART use, infant mortality and replacement feeding risk.

Mallampati D, MacLean RL, Shapiro R, Dabis F, Engelsmann B, Freedberg KA, Leroy V, Lockman S, Walensky R, Rollins N, Ciaranello A.

J Int AIDS Soc. 2018 Apr;21(4):e25107. doi: 10.1002/jia2.25107.

24.

Clinical Benefits and Cost-Effectiveness of Laboratory Monitoring Strategies to Guide Antiretroviral Treatment Switching in India.

Freedberg KA, Kumarasamy N, Borre ED, Ross EL, Mayer KH, Losina E, Swaminathan S, Flanigan TP, Walensky RP.

AIDS Res Hum Retroviruses. 2018 Jun;34(6):486-497. doi: 10.1089/AID.2017.0258. Epub 2018 May 3.

25.

The cost-effectiveness of HIV pre-exposure prophylaxis in men who have sex with men and transgender women at high risk of HIV infection in Brazil.

Luz PM, Osher B, Grinsztejn B, Maclean RL, Losina E, Stern ME, Struchiner CJ, Parker RA, Freedberg KA, Mesquita F, Walensky RP, Veloso VG, Paltiel AD.

J Int AIDS Soc. 2018 Mar;21(3):e25096. doi: 10.1002/jia2.25096.

26.

The cost-effectiveness and budgetary impact of a dolutegravir-based regimen as first-line treatment of HIV infection in India.

Zheng A, Kumarasamy N, Huang M, Paltiel AD, Mayer KH, Rewari BB, Walensky RP, Freedberg KA.

J Int AIDS Soc. 2018 Mar;21(3):e25085. doi: 10.1002/jia2.25085.

27.

High Medication Possession Ratios Associated With Greater Risk of Virologic Failure Among Youth Compared With Adults in a Nigerian Cohort.

Ahonkhai AA, Banigbe B, Adeola J, Bassett IV, Idigbe I, Okonkwo P, Freedberg KA, Regan S, Losina E.

J Acquir Immune Defic Syndr. 2018 Jul 1;78(3):322-328. doi: 10.1097/QAI.0000000000001670.

28.

The Optimal Age for Screening Adolescents and Young Adults Without Identified Risk Factors for HIV.

Neilan AM, Dunville R, Ocfemia MCB, Salomon JA, Francke JA, Bulteel AJB, Wang LY, Hsu KK, DiNenno EA, Walensky RP, Parker RA, Freedberg KA, Ciaranello AL.

J Adolesc Health. 2018 Jan;62(1):22-28. doi: 10.1016/j.jadohealth.2017.08.028.

29.

Hepatitis C Testing Increased Among Baby Boomers Following The 2012 Change To CDC Testing Recommendations.

Barocas JA, Wang J, White LF, Tasillo A, Salomon JA, Freedberg KA, Linas BP.

Health Aff (Millwood). 2017 Dec;36(12):2142-2150. doi: 10.1377/hlthaff.2017.0684.

30.

The value of confirmatory testing in early infant HIV diagnosis programmes in South Africa: A cost-effectiveness analysis.

Dunning L, Francke JA, Mallampati D, MacLean RL, Penazzato M, Hou T, Myer L, Abrams EJ, Walensky RP, Leroy V, Freedberg KA, Ciaranello A.

PLoS Med. 2017 Nov 21;14(11):e1002446. doi: 10.1371/journal.pmed.1002446. eCollection 2017 Nov.

31.

Using Observational Data to Calibrate Simulation Models.

Murray EJ, Robins JM, Seage GR 3rd, Lodi S, Hyle EP, Reddy KP, Freedberg KA, Hernán MA.

Med Decis Making. 2018 Feb;38(2):212-224. doi: 10.1177/0272989X17738753. Epub 2017 Nov 15.

32.

The Clinical and Economic Impact of Attaining National HIV/AIDS Strategy Treatment Targets in the United States.

Borre ED, Hyle EP, Paltiel AD, Neilan AM, Sax PE, Freedberg KA, Weinstein MC, Walensky RP.

J Infect Dis. 2017 Oct 17;216(7):798-807. doi: 10.1093/infdis/jix349.

33.

The patient-centered medical home: a reality for HIV care in Nigeria.

Ahonkhai AA, Onwuatuelo I, Regan S, Adegoke A, Losina E, Banigbe B, Adeola J, Ferris TG, Okonkwo P, Freedberg KA.

Int J Qual Health Care. 2017 Oct 1;29(5):654-661. doi: 10.1093/intqhc/mzx083.

34.

Clinic-Based Urinary Lipoarabinomannan as a Biomarker of Clinical Disease Severity and Mortality Among Antiretroviral Therapy-Naive Human Immunodeficiency Virus-Infected Adults in South Africa.

Drain PK, Losina E, Coleman SM, Giddy J, Ross D, Katz JN, Freedberg KA, Bassett IV.

Open Forum Infect Dis. 2017 Aug 14;4(3):ofx167. doi: 10.1093/ofid/ofx167. eCollection 2017 Summer.

35.

Lung Cancer Mortality Associated With Smoking and Smoking Cessation Among People Living With HIV in the United States.

Reddy KP, Kong CY, Hyle EP, Baggett TP, Huang M, Parker RA, Paltiel AD, Losina E, Weinstein MC, Freedberg KA, Walensky RP.

JAMA Intern Med. 2017 Nov 1;177(11):1613-1621. doi: 10.1001/jamainternmed.2017.4349.

36.

The value of point-of-care CD4+ and laboratory viral load in tailoring antiretroviral therapy monitoring strategies to resource limitations.

Hyle EP, Jani IV, Rosettie KL, Wood R, Osher B, Resch S, Pei PP, Maggiore P, Freedberg KA, Peter T, Parker RA, Walensky RP.

AIDS. 2017 Sep 24;31(15):2135-2145. doi: 10.1097/QAD.0000000000001586.

37.

Do Less Harm: Evaluating HIV Programmatic Alternatives in Response to Cutbacks in Foreign Aid.

Walensky RP, Borre ED, Bekker LG, Hyle EP, Gonsalves GS, Wood R, Eholié SP, Weinstein MC, Anglaret X, Freedberg KA, Paltiel AD.

Ann Intern Med. 2017 Nov 7;167(9):618-629. doi: 10.7326/M17-1358. Epub 2017 Aug 29.

38.

A Comparison of Agent-Based Models and the Parametric G-Formula for Causal Inference.

Murray EJ, Robins JM, Seage GR, Freedberg KA, Hernán MA.

Am J Epidemiol. 2017 Jul 15;186(2):131-142. doi: 10.1093/aje/kwx091.

39.

Setting Performance Standards for a Cost-Effective Human Immunodeficiency Virus Cure Strategy in South Africa.

Paltiel AD, Zheng A, Weinstein MC, Gaynes MR, Wood R, Freedberg KA, Sax PE, Walensky RP.

Open Forum Infect Dis. 2017 Apr 22;4(2):ofx081. doi: 10.1093/ofid/ofx081. eCollection 2017 Spring.

40.

Projecting 10-year, 20-year, and Lifetime Risks of Cardiovascular Disease in Persons Living With Human Immunodeficiency Virus in the United States.

Losina E, Hyle EP, Borre ED, Linas BP, Sax PE, Weinstein MC, Rusu C, Ciaranello AL, Walensky RP, Freedberg KA.

Clin Infect Dis. 2017 Oct 15;65(8):1266-1271. doi: 10.1093/cid/cix547.

41.

Cost Effectiveness and Cost Containment in the Era of Interferon-Free Therapies to Treat Hepatitis C Virus Genotype 1.

Linas BP, Morgan JR, Pho MT, Leff JA, Schackman BR, Horsburgh CR, Assoumou SA, Salomon JA, Weinstein MC, Freedberg KA, Kim AY.

Open Forum Infect Dis. 2016 Dec 27;4(1):ofw266. doi: 10.1093/ofid/ofw266. eCollection 2017 Winter.

42.

Impact of Medication Adherence on Virologic Failure in A5202: A Randomized, Partially Blinded, Phase 3B Study.

Parker RA, Rabideau DJ, Sax PE, Tierney C, Daar ES, Collier AC, Losina E, Freedberg KA.

Clin Infect Dis. 2017 Jun 1;64(11):1612-1614. doi: 10.1093/cid/cix176.

43.

Adolescent Linkage to Care After a Large-scale Transfer From a Hospital-based HIV Clinic to the Public Sector in South Africa.

Ramirez-Avila L, Regan S, Cloete C, Crankshaw T, Rabideau DJ, Freedberg KA, Parker RA, Walensky RP, Losina E, Bassett IV.

Pediatr Infect Dis J. 2017 Mar;36(3):311-313. doi: 10.1097/INF.0000000000001392.

44.

Impact of Unplanned Care Interruption on CD4 Response Early After ART Initiation in a Nigerian Cohort.

Ahonkhai AA, Adeola J, Banigbe B, Onwuatuelo I, Adegoke AB, Bassett IV, Losina E, Freedberg KA, Okonkwo P, Regan S.

J Int Assoc Provid AIDS Care. 2017 Jan/Feb;16(1):98-104. doi: 10.1177/2325957416672010. Epub 2016 Oct 10.

45.

Barriers to Care and 1-Year Mortality Among Newly Diagnosed HIV-Infected People in Durban, South Africa.

Bassett IV, Coleman SM, Giddy J, Bogart LM, Chaisson CE, Ross D, Flash MJ, Govender T, Walensky RP, Freedberg KA, Losina E.

J Acquir Immune Defic Syndr. 2017 Apr 1;74(4):432-438. doi: 10.1097/QAI.0000000000001277.

46.

Improving on effective antiretroviral therapy: how good will a cure have to be?

Freedberg KA, Sax PE.

J Med Ethics. 2017 Feb;43(2):71-73. doi: 10.1136/medethics-2016-103907. Epub 2016 Dec 5. No abstract available.

47.

Impact of Cigarette Smoking and Smoking Cessation on Life Expectancy Among People With HIV: A US-Based Modeling Study.

Reddy KP, Parker RA, Losina E, Baggett TP, Paltiel AD, Rigotti NA, Weinstein MC, Freedberg KA, Walensky RP.

J Infect Dis. 2016 Dec 1;214(11):1672-1681. Epub 2016 Nov 3.

48.

Topical gentian violet compared with nystatin oral suspension for the treatment of oropharyngeal candidiasis in HIV-1-infected participants.

Mukherjee PK, Chen H, Patton LL, Evans S, Lee A, Kumwenda J, Hakim J, Masheto G, Sawe F, Pho MT, Freedberg KA, Shiboski CH, Ghannoum MA, Salata RA; Oral HIVAIDS Research Alliance (OHARA)AIDS Clinical Trials Group (ACTG) 5265 Team.

AIDS. 2017 Jan 2;31(1):81-88.

49.

Sizanani: A Randomized Trial of Health System Navigators to Improve Linkage to HIV and TB Care in South Africa.

Bassett IV, Coleman SM, Giddy J, Bogart LM, Chaisson CE, Ross D, Jacobsen MM, Robine M, Govender T, Freedberg KA, Katz JN, Walensky RP, Losina E.

J Acquir Immune Defic Syndr. 2016 Oct 1;73(2):154-60. doi: 10.1097/QAI.0000000000001025.

50.

Clinical Impact and Cost-effectiveness of Diagnosing HIV Infection During Early Infancy in South Africa: Test Timing and Frequency.

Francke JA, Penazzato M, Hou T, Abrams EJ, MacLean RL, Myer L, Walensky RP, Leroy V, Weinstein MC, Parker RA, Freedberg KA, Ciaranello A.

J Infect Dis. 2016 Nov 1;214(9):1319-1328. Epub 2016 Aug 17.

Supplemental Content

Loading ...
Support Center